Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically inherited ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess its impact on cardiovascular events.

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

April 2 (UPI) --Heart disease experts are hailing the results of a clinical trial that showed a strongly positive performance by Eli Lilly's drug lepodisiran, which inhibits the body's production ...